FCGR2B and chronic myelogenous leukemia, BCR-ABL1 positive: Next, we applied shRNA-mediated knockdown of FcγRIIb in vitro and in vivo using the SCLtTA/Bcr-Abl transgenic CML mouse model (Fig. 3a, model B).